Impact of the Choice of 3rd Generation Cephalosporins on the Emergence of Resistance in the Microbiota Intestinal.
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
CEREMI is an open, randomised prospective study in parallel groups in healthy volunteers.
This study compare the effect of a monotherapy by ceftriaxone or cefotaxime on the emergence
of resistance of enterobacteria to 3rd-generation cephalosporins within the intestinal
microbiota. Each volunteer will be treated for 3 days by either ceftriaxone (1 gram per day)
or cefotaxime (1 gram every 8 hours).